Reply to Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?

Summary: This study evaluated the safety, tolerability, and antitumor activity of durvalumab monotherapy and durvalumab plus tremelimumab combination therapy in Asian patients with biliary tract cancer, esophageal squamous cell carcinoma, or head and neck squamous cell carcinoma. The results demonstrated acceptable safety profiles and clinical benefit in these patients.

Summary: The study demonstrates the potential clinical activity of using checkpoint inhibitors in patients with rare solid tumors, highlighting the feasibility of aggregating such patients into cohorts for clinical trials.